Article: article from journal or magazin.
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Telmisartan: a different angiotensin II receptor blocker protecting a different population?
Journal of International Medical Research
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET()) showed that the angiotensin II receptor blocker (ARB) telmisartan was as protective as the reference-standard ramipril in a broad cross-section of patients at increased cardiovascular risk, but was better tolerated. Telmisartan has a unique profile among ARBs, with a high affinity for the angiotensin II type 1 receptor, a long duration of receptor binding, a high lipophilicity and a long plasma half life. This leads to sustained and powerful blood pressure lowering when compared with the first marketed ARBs, such as losartan and valsartan. Some pharmacological properties of telmisartan clearly distinguish it from other members of the ARB class and may contribute to the clinical effects seen with telmisartan. A class effect for ARBs cannot be assumed. To date, telmisartan is the only ARB that has been shown to reduce cardiovascular risk in at-risk cardiovascular patients.
Telmisartan, Angiotensin II Receptor Blocker, Cardiovascular Disease, Cardiovascular Protection, Cardiovascular Risk, Pharmacodynamics, Pharmacokinetics, Left-Ventricular Hypertrophy, Ambulatory Blood-Pressure, To-Moderate Hypertension, Converting Enzyme-Inhibitors, Improves Insulin-Resistance, Gamma-Modulating Activity, Type-2 Diabetic-Patients, End-Point Reduction, High-Risk Patients, E-Deficient Mice
Web of science
Last modification date